India, Dec. 18 -- image credit- freepik

AstraZeneca Pharma India Ltd. (AZPIL), has announced that theCentral Drugs Standard Control Organisation (CDSCO)has granted regulatory approval to import, sell, and distributeDatopotamab Deruxtecan (Dato-DXd)in India.

The approval reflects AstraZeneca's focus on bringing to life-changing medicines at a rapid pace and marks its second antibody-drug conjugate (ADC) approval in India after trastuzumab deruxtecan (T-DXd). Further information on potential launch timeline in India will be shared post all necessary approvals are obtained.

Dato-DXd is a novel,TROP2-directed antibody drug conjugate (ADC)developed for the treatment of adult patients withunresectable or metastatic hormone receptor (HR)-posi...